APP and Alzheimer disease: Biomarker, modeling, biophysical and pathological studies all show that mutations in APP or PSEN1/2 associated with early onset Familial AD (EOFAD) result in changes to APP processing or Aβ itself, in a way that promotes Aβ aggregation.